Form 4: Boston Scientific Exec's RSU Vesting & Tax Sale

Boston Scientific's SVP, Global Controller and CAO, Emily Woodworth, reported the vesting of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Summary

• Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific Corp (BSX), reported transactions on March 1, 2026.
• 838 Restricted Stock Units (RSUs) vested, converting into 838 shares of Boston Scientific common stock at a price of $0.00.
• Concurrently, 372 shares of common stock were disposed of at $76.85 per share, primarily to cover tax obligations related to the RSU vesting.
• Following these transactions, Woodworth beneficially owns 2,859 shares of common stock and 1,676 unvested Restricted Stock Units.
• Each RSU represents the company's commitment to issue one share of Boston Scientific common stock.
• Shares of common stock from RSU grants are issued to the reporting person in four equal annual installments, with the first installment beginning on March 1, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting a standard executive compensation process where long-term incentives are vesting, indicating continued executive alignment, despite a minor tax-related sale.

Positives

• The vesting of 838 Restricted Stock Units indicates continued long-term incentive alignment between management and shareholders.
• The transaction reflects a standard compensation event for a senior executive, demonstrating the execution of established incentive plans.

Negatives

• The disposition of 372 shares, while for tax purposes, results in a reduction of the direct shareholding of a key executive.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports past insider transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for public company executives, detailing changes in their beneficial ownership. These transactions, particularly RSU vestings and associated tax sales, are common events in executive compensation structures across the medical device industry, reflecting the long-term incentive plans designed to align executive interests with shareholder value.

Comparison to Industry Standards

• These types of RSU vesting and tax-related sales are standard practice for executive compensation in large-cap medical device companies like Medtronic (MDT), Johnson & Johnson (JNJ), and Abbott Laboratories (ABT).
• The structure of multi-year vesting for RSUs is a common mechanism to encourage long-term executive retention and performance, aligning with global benchmarks for executive incentive plans.

Related Party Transactions

• The transaction involves the vesting of Restricted Stock Units and subsequent sale of shares by a senior executive of Boston Scientific, which is a standard related-party compensation event.

Stakeholder Impact

• Shareholders: The vesting of RSUs aligns executive interests with long-term shareholder value. The tax-related sale is a minor, routine event with negligible impact on overall share float or price.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Continued vesting of the remaining 1,676 Restricted Stock Units according to the four equal annual installment schedule.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and tax-related share sale) and does not provide new material information that would alter the fundamental investment thesis for Boston Scientific. Investors should continue to hold based on broader company performance and market conditions, not on this standard insider transaction.

Keywords

Boston Scientific, BSX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Emily Woodworth, Stock Sale, Tax Withholding